Blocking the immune protein Granzyme K reduces age-related damage in vital organs such as the heart, liver, and kidneys, according to research published in the journal Immunity.
Monash University researchers found that levels of Granzyme K increase significantly with age in both mice and humans. Until now, the precise role of this protein in driving tissue deterioration remained unclear.
“We know that as we get older, our organs undergo changes that can make us more susceptible to diseases, including heart and kidney disease,” Professor Nicole La Gruta, senior researcher from the Monash Biomedicine Discovery Institute, told News-Medical.
“What we’ve discovered is that Granzyme K plays an important role in driving some of that damage,” she said.
- Protein Target: Granzyme K is an immune system protein that accumulates in tissues as we age, contributing to organ scarring and functional decline.
- Independent Aging: Animal models show that organ aging and immune system aging are not strictly tied together, meaning organ damage can potentially be halted independently.
- Future Therapeutics: Researchers are now testing whether selectively blocking this protein later in life can replicate the protective effects seen in subjects born without it.
The study utilized preclinical mouse models to compare older animals possessing Granzyme K against those lacking the protein entirely. Subjects without Granzyme K demonstrated significantly improved heart function and reduced fibrosis, a form of pathological scarring that impairs organ efficiency.
These mice also displayed diminished signs of age-related deterioration across hepatic and renal tissues. Researchers analyzing human datasets subsequently identified elevated levels of Granzyme K in patients suffering from inflammatory and fibrotic conditions, including heart failure and lupus nephritis.
“What’s particularly exciting is that mice without this protein showed reduced signs of organ ageing, even though their immune systems continued to age normally,” Professor La Gruta told News-Medical, noting that the findings challenge the long-held assumption that organ and immune aging are inextricably linked.
Chronological aging remains one of the primary epidemiological risk factors for chronic cardiovascular and renal disorders. Accumulating tissue damage leaves populations increasingly vulnerable to severe morbidity later in life.
The research team is currently investigating pharmacological methods to selectively inhibit Granzyme K activity. Evaluating whether therapeutic intervention late in life yields protective outcomes comparable to lifelong absence represents a major hurdle for clinical translation.
“Because these mice have lived their entire lives without Granzyme K, we now need to understand whether blocking the protein later in life could achieve similar benefits,” Professor La Gruta told News-Medical.
“Further research is also needed to determine whether the same benefits could be achieved in humans. There’s still a lot of work to do, but identifying a protein that contributes to damage across multiple organs gives us a promising new direction for research into healthier aging,” she said.
| Parameter | Observed Effect in Granzyme K-Deficient Models |
|---|---|
| Cardiac Function | Significantly improved performance |
| Fibrosis | Reduced scarring across vital tissues |
| Target Organs | Heart, liver, and kidneys protected |
Because therapeutic blockers for Granzyme K are currently under early preclinical investigation, no clinical guidelines or approved medications exist for patient use.
- Monash University Biomedicine Discovery Institute. Research published in Immunity. DOI: 10.1016/j.immuni.2026.10.013.
Disclaimer: This article is intended for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding any questions about a medical condition.
